GlaxoSmithKline plc (LON:GSK) has been assigned a consensus recommendation of “Hold” from the eighteen ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is GBX 1,597.92 ($20.88).
Several equities analysts recently commented on the stock. Goldman Sachs Group set a GBX 1,900 ($24.83) price target on shares of GlaxoSmithKline and gave the company a “buy” rating in a report on Monday, December 31st. Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a report on Tuesday, December 4th. UBS Group reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, March 19th. Morgan Stanley set a GBX 1,460 ($19.08) price target on shares of GlaxoSmithKline and gave the company a “sell” rating in a report on Friday, December 14th. Finally, Cfra set a GBX 1,620 ($21.17) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Tuesday, December 4th.
Shares of LON GSK traded up GBX 6.80 ($0.09) during mid-day trading on Friday, hitting GBX 1,596.80 ($20.87). 10,125,949 shares of the company’s stock traded hands, compared to its average volume of 9,120,000. The company has a current ratio of 0.75, a quick ratio of 0.47 and a debt-to-equity ratio of 709.80. The stock has a market capitalization of $78.56 billion and a price-to-earnings ratio of 21.90. GlaxoSmithKline has a 1 year low of GBX 1,281.60 ($16.75) and a 1 year high of GBX 1,648.80 ($21.54).
In related news, insider Jesse Goodman bought 845 shares of the company’s stock in a transaction on Wednesday, February 6th. The shares were acquired at an average cost of GBX 1,964 ($25.66) per share, for a total transaction of £16,595.80 ($21,685.35). Also, insider Victoria Whyte bought 3,020 shares of the company’s stock in a transaction on Wednesday, February 13th. The stock was bought at an average price of GBX 1,547 ($20.21) per share, for a total transaction of £46,719.40 ($61,047.17). Insiders acquired a total of 3,881 shares of company stock worth $6,356,144 over the last 90 days.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.